Review Article
New Insights into Biology, Prognostic Factors, and Current Therapeutic Strategies in Chronic Lymphocytic Leukemia
Table 2
Relapsed/refractory immunochemotherapy for CLL patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
: number of patients in the trial, CR: complete response, OR: overall response, OS: overall survival, PFS: progression-free survival, ND: no data, FC: fludarabine and cyclophosphamide, RFC: rituximab, fludarabine, and cyclophosphamide, RC: rituximab, cladribine and RCC: rituximab, cladribine, and cyclophosphamide, PAR: pentostatin, alemtuzumab, and rituximab, CFAR: cyclophosphomide, fludarabine, alemtuzumab, and rituximab, HDMP: high-dose methylprednisolone, BF-ref: fludarabine refractory, FA-ref: fludarabine and alemtuzumab refractory. |